. 2021 Nov 3;27(6):768–773. doi: 10.5152/dir.2021.20785

Table 4.

Tumor type analysis in the ARC group

Tumor type	Characteristics		MAA	⁹⁰Y	p
Hepatocellular carcinoma n= 24 (20.9%)	T/NL	Median (IQR)	2.06 (2.10)	2.80(1.94)	0.010^*
Hepatocellular carcinoma n= 24 (20.9%)	Dose	Median (IQR)	95.36 (110.79)	135.23 (116.40)	0.034^*

Neuroendocrine metastases n= 30 (26.1%)	T/NL	Median (IQR)	1.88 (1.30)	2.97(4.34)	<0.001^*
Neuroendocrine metastases n= 30 (26.1%)	Dose	Median (IQR)	80.89 (63.52)	125.16 (127.07)	0.009^*

Colorectal metastases n=48 (41.7%)	T/NL	Median (IQR)	1.57 (1.01)	1.80(1.18)	0.162
Colorectal metastases n=48 (41.7%)	Dose	Median (IQR)	62.22 (62.93)	70.26 (72.97)	0.039^*

ARC, antireflux catheter; MAA, macroaggregated albumin; IQR, interquartile range; T/NL, tumor to normal liver uptake.

Wilcoxon signed rank test was used for the analysis of patient-paired difference between MAA and ⁹⁰Y.

Indicates a significant result at a 5% type I error.